israel journal of
psychiatry
Ma n a gi n g s u b o p t i m a l res p o ns e to antid ep res s ant therapy
Seroquel XR הוספת
50% -הוכחה כמשפרת בכ
את סיכויי ההגעה לרמיסייה בדיכאון
Culture and Psychiatry
Vol. 49 - Number 3 2012
ISSN: 0333-7308
151 Psychiatric services and Ethiopians in Israel
2
בהשוואה לטיפול בנוגד דיכאון בלבד
Rafael Youngmann et al.
159 Volume 49, Number 3, 2012 Israel Journal of Psychiatry and Related Sciences
-on
d d A
חדש Seroquel XR is indicated for add-on treatment of major depressive episodes in patients with major depressive disorder (MDD) who have had suboptimal response to antidepressant monotherapy.1 The recommended daily dose is 150mg, however if clinically justified the dose may be increase to 300mg. Seroquel XR is also indicated for schizophrenia and bipolar.1
08-13-SER-12-IL-030
References: 1. Seroquel XR MoH Approved Prescribing Information 2. Bauer et al. Journal of Affective Disorders 2010; 127:19–30
09-7406528 : טלפון,43656 רעננה4070 .ד.ת Israel.infoisrael@astrazeneca.com 09-7406529 :פקס Seroquel XR® is a registered trademark of AstraZeneca group of companies. The AstraZeneca logo is a trademark of AstraZeneca group of companies
Mental health of Jews in the U.K. Kate Miriam Loewenthal
167 Community study of Bedouin servicemen Yael Caspi and Ehud Klein
178 Female circumcision RH Belmaker
184 Attachment patterns of Arabs and Jews Shiri Lavy et al.
194 Sociocultural information at intake Margarita Alegria et al.
202 Social identities and mental health disparities Ora Nakash et al.
MDD (Add-on)
150mg
עכשיו מאושרת בישראל 1 כתוספת לטיפול בדיכאון חדש זמינה כטיפול לדיכאון בביטוח המשלים של חלק מקופות החולים
211 Palestinian families and War in Israel Khawla Abu-Baker
219 A women's counselling service in the Negev Julie Cwikel and Andrea Ifergane
227 Cultural competence training Julia Mirsky